@ProfClark

Helmut Ecker Endowed Professor of AMD & Co-Founder - Complement Therapeutics. A British Biochemist in Europe 🇬🇧 🇪🇺 @prof-clark.bsky.social

 TĂĽbingen, Germany
eye-tuebingen.de/clark/
Joined June 2021
  • Tweets585
  • Following186
  • Followers220
54Media
In a US study of 77 patients with geographic atrophy, preserving reading drove treatment choices and 86% preferred a one-time injection. buff.ly/m5SVyc7 #AMD #Retina #GeographicAtrophy

US Patients’ Preferences for Geographic Atrophy Treatment | OPTH | Dove Medical Press

2 complement inhibitors used for treating geographic atrophy secondary to age-related macular degeneration and other treatments are being developed

dovepress.com
26
The devil is in the detail! Current prognostic biomarker screening in cancer forcuses on only one transcript from the CFH gene. Does this compound results and understanding buff.ly/geDixq0 #complement #cancer #biomarker #prognostic #gene #transcription #diagnosis #CFH

Diagnostic interpretation of CFH expression in pan-cancer analyses: the importance of factor H–like...

BMC Cancer - Recent pan-cancer analyses have identified Complement Factor H (CFH) expression as an immune-related and prognostic biomarker. However, interpretation of CFH transcriptional data...

link.springer.com
21
Come! Join us. 🎓️ PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct. Follow the link for details - buff.ly/sYJ4JCN #PhD #research #AMD #complement #ophthalmology
1
35
MAC in the ageing choroid may be more widespread than expected—highest on macrophages, pericytes & smooth muscle cells. #AMD #Complement #Ophthalmology buff.ly/hhhvX3U
28
Come! Join us. 🎓️ PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct. Follow the link for details - buff.ly/sYJ4JCN #PhD #research #AMD #complement #ophthalmology
1
52
Could functional vision be the future of retinal gene-therapy approvals? Beacon’s VISTA win in XLRP puts patient-relevant vision outcomes centre stage. #GeneTherapy #Ophthalmology buff.ly/MODKvwq

Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy

Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. | Beacon Therapeutics has found the light in a rare vision loss disease that has left...

fiercebiotech.com
59
Factor H deficiency reveals a potential complement–EV–macrophage axis in kidney inflammation, opening new questions about how complement dysregulation drives tissue injury. #Complement #Immunology buff.ly/3Nyo2Td

Complement Factor H Regulates a Complement-Extracellular Vesicle-Macrophage Axis in Immune Mediated...

Introduction: Complement Factor H (FH) regulates the alternative complement pathway, and FH deficiency promotes complement activation, macrophage recruitment, and renal injury. Extracellular vesicles...

pubmed.ncbi.nlm.nih.gov
26
Come! Join us. 🎓️ PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct. Follow the link for details - buff.ly/sYJ4JCN #PhD #research #AMD #complement #ophthalmology
2
61
GOLDEN shows that systemic factor B suppression can engage complement without slowing GA progression—an important lesson for complement-targeted AMD therapy. #AMD #Complement #Retina #DrugDevelopment buff.ly/zGZEnsf

GOLDEN: Efficacy and Safety of Complement Factor B Antisense, Sefaxersen, in Geographic Atrophy due...

To evaluate the efficacy and safety of sefaxersen, an investigational antisense oligonucleotide targeting complement factor B (FB), in slowing the progression of geographic atrophy (GA) secondary to...

ophthalmologyscience.org
29
AI may transform AMD drug discovery, but algorithms generate hypotheses, not biological proof. Validation, generalisability and mechanism remain the real tests. #AI #AMD #DrugDiscovery buff.ly/9wRiLTr

Artificial intelligence for precision therapeutics in age-related macular degeneration: current...

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide and is characterized by substantial clinical, imaging, and molecular heterogeneity that complicates...

pubmed.ncbi.nlm.nih.gov
26
ADARx’s planned IPO could signal growing confidence in complement therapeutic, with a CFB-targeting siRNA advancing into AMD geographic atrophy. Could durable complement suppression be the next step for AMD? #AMD #Complement #siRNA #GeneSilencing buff.ly/K4O3O33

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical trials of a range of next-gen small interfering RNA (siRNA) medicines. |...

fiercebiotech.com
43
Is the RPE the wrong place to look for pyroptosis in AMD? New single-cell data instead point to a distinct macrophage state, with NLRP3 and STAT3 emerging as potential regulators of inflammatory remodelling. #AMD #Retina #Ophthalmology #Pyroptosis buff.ly/sLa0yGL
40
Could chronic choriocapillaris hypoperfusion be a unifying driver of AMD? A new review challenges how we connect vascular, genetic & complement risk. #AMD #Retina buff.ly/WGXrWNS

The perfusion-based model of AMD: Moving towards a unifying hypothesis - PubMed

Age-related macular degeneration (AMD) is a complex disease wherein age, genetics, and environment play a role. How each of these factors contribute to the overall disease initiation and progression...

pubmed.ncbi.nlm.nih.gov
42
Could AMD leave a molecular fingerprint in the blood? New EV profiling reveals systemic signatures of complement, oxidative stress & lipid dysregulation. #AMD #Biomarkers #Complement buff.ly/1n5qVWa

Systematic Analysis of Plasma-Derived Extracellular Vesicle-Enriched Samples in Age-Related Macular...

Vision impairment caused by age-related macular degeneration (AMD) is a global health priority. Retinal pathology is driven by ageing and exacerbated by genetic and environmental risk factors....

pubmed.ncbi.nlm.nih.gov
25
Factor D inhibition failed to slow GA in Phase 2 OnwarD, raising a key question for AMD: target, timing, tissue penetration, or degree of complement inhibition? #AMD #Complement buff.ly/8LUsGO5

Danicopan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results From the...

To investigate the efficacy, safety, and pharmacokinetics of the oral complement factor D inhibitor danicopan for the treatment of geographic atrophy (GA) secondary to age-related macular degenerat...

ophthalmologyscience.org
53
Could pharma mega-mergers ultimately boost biotech M&A? Integration risk may push Big Pharma toward targeted acquisitions of differentiated, clinical-stage assets. #Biotech #M&A #Pharma buff.ly/vZnxuZj

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired Allergan, and Bristol Myers Squibb swallowed Celgene. | Combining the two...

fiercebiotech.com
46
It's pretty cool to finally see a method capable of generating practical amounts of functional, full-length complement factor H. buff.ly/xwEz6YD #ComplementTherapeutics #ComplementSystem #Immunology #DrugDevelopment #BiotechInnovation #TranslationalMedicine

Moss-derived recombinant Factor H, CPV-104, effectively antagonizes alternative pathway C3/C5...

CPV-104 effectively limits both stabilization and formation of AP C3 convertases in NeF-positive C3G, demonstrating superior functional activity compared with sd-FH. By restoring physiological AP...

pubmed.ncbi.nlm.nih.gov
27
Jasper-Kira merger highlights the next wave of complement therapeutics: dual-pathway inhibition and next-gen immune modulation could reshape treatment of complement-driven diseases. buff.ly/vjXHLY3 #Complement #Biotech #Immunology

Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but not all of Kira's pipeline is coming along for the ride. | Jasper Therap...

fiercebiotech.com
64
New roadmap says the FDA aims within three to five years to make animal studies the exception, rather than the norm, in preclinical safety and toxicity testing. #DrugDevelopment #Biotech #RegulatoryScience #ClinicalTrials #FDA #NewApproachMethodologies buff.ly/7qPDRQP

House passes bill directing FDA to update animal testing rules

The U.S. | The U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates are celebrating the bill as a step toward a new era in precli...

fiercebiotech.com
1
27
Restoring lysosomal function prevents drusen-like deposits and RPE degeneration in inherited macular disease, revealing a promising therapeutic pathway with major implications for #AMD. #Retina #VisionResearch #Ophthalmology #CellBiology buff.ly/7Vqe4fF

Restoration of impaired lysosomal function mitigates drusen-like deposit formation and cell death...

Malattia Leventinese (MAL) is an inherited macular degeneration disorder characterized by retinal drusen formation in adolescence, leading to vision loss. A mutation in the fibulin-3 gene (EFEMP1)...

pubmed.ncbi.nlm.nih.gov
21
Load more